Alzheimer's disease: Genes, pathogenesis and risk prediction

Community Genetics

Volumn 4, Issue 4, 2001, Pages 197-203

  Sleegers, K ^a   Van Duijn, C M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Amyloid; Alzheimer's disease; Genetic counselling; Genetic epidemiology; Pathogenesis; Risk prediction

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; PRESENILIN 1; PRESENILIN 2;

AGING; ALZHEIMER DISEASE; DEMENTIA; DISEASE DURATION; ENVIRONMENTAL FACTOR; GENE FREQUENCY; GENE MUTATION; GENETIC COUNSELING; GENETIC EPIDEMIOLOGY; GENETIC RISK; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; MORBIDITY; MORTALITY; NEUROFIBRILLARY TANGLE; PATHOGENESIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR;

EID: 0035744505     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064193     Document Type: Review

References (86)

1. Genetic epidemiology of Alzheimer's disease
2. The genetic defect causing familial Alzheimer's disease maps on chromosome 21
3. Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus
4. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
5. Molecular genetics of Alzheimer disease: Identification of genes and gene mutations
6. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14
7. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14
8. A locus for familial early-onset Alzheimer's disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene
9. Mapping of a gene predisposing to early-onset Alzheimer's disease to chromosome 14q24.3
10. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
11. Candidate gene for the chromosome 1 familial Alzheimer's disease locus
12. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene
13. Cortical dementias: Alzheimer's disease and other cortical degenerations
14. Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease
15. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
16. Neuropathological stageing of Alzheimer-related changes
17. Tau pathology: A marker of neurodegenerative disorders
18. Frequency and distribution of Alzheimer's disease in Europe: A collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group
19. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group
20. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group
21. Piecing together Alzheimer's
22. Epidemiology of the dementias: Recent developments and new approaches
23. 15-year longitudinal study of blood pressure and dementia
24. Untreated blood pressure level is inversely related to cognitive functioning: The Framingham Study
25. Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: The Rotterdam Study
26. Diabetes mellitus and the risk of dementia: The Rotterdam Study
27. Risk of dementia among persons with diabetes mellitus: A population-based cohort study
28. Smoking and Alzheimer's disease: A review of the epidemiological evidence
29. The influence of smoking on the risk of Alzheimer's disease
30. Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: A population-based case-control study
31. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
32. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease
33. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study
34. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana
35. Familial aggregation of Alzheimer's disease and related disorders: A collaborative re-analysis of case-control studies
36. Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions
37. Genetic transmission of Alzheimer's disease among families in a Dutch population based study
38. Multiple etiologies for Alzheimer disease are revealed by segregation analysis
39. Genetic testing should not be advocated as a diagnostic tool in familial forms of dementia
40. Molecular genetics of Alzheimer's disease
41. Estimation of the genetic contribution of presenil-in-1 and -2 mutations in a population-based study of presenile Alzheimer disease
42. Genetic and environmental factors in Alzheimer's disease
43. Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage
44. High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease
45. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease
46. Genetic risk of Alzheimer's disease: Advising relatives
47. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium
48. APOE genotype predicts when - Not whether - One is predisposed to develop Alzheimer disease
49. Biochemical detection of Abeta isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease
50. Amyloid, the presenilins and Alzheimer's disease
51. Molecular genetics of Alzheimer's disease: The role of beta-amyloid and the presenilins
52. The origins of Alzheimer disease: A is for Amyloid
53. Alzheimer's disease: A central role for amyloid
54. A causal role for amyloid in Alzheimer's disease: The end of the beginning
55. The molecular and genetic basis of AD: The end of the beginning: The 2000 Wartenberg lecture
56. The role of A beta 42 in Alzheimer's disease
57. Genetic factors in the genesis of Alzheimer's disease
58. A transcriptively active complex of APP with Fe65 and histone acetyl-transferase Tip60
59. Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation
60. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor
61. APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1-42/43 and a beta 1-40) in familial Alzheimer's disease brain
62. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43)
63. Seeding 'one-dimensional crystallization' of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie?
64. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
65. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice
66. Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo
67. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins
68. Increased Abeta42(43) from cell lines expressing presenilin 1 mutations
69. Binding to soluble Alzheimer's beta-amyloid
70. Alzheimer's disease. A role in amyloid catabolism
71. The 'amyloid cascade hypothesis' of AD: Decoy or real McCoy?
72. Copernicus revisited: Amyloid beta in Alzheimer's disease
73. Arson. Tracking the culprit in Alzheimer's disease
74. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline
75. Alzheimer's amyloid hypothesis gains support
76. A very incomplete comprehensive theory of Alzheimer's disease
77. A plasticity-based theory of the pathogenesis of Alzheimer's disease
78. Oxidative stress and Alzheimer disease
79. Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer's disease
80. Inflammation and Alzheimer's disease pathogenesis
81. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum
82. APOE genotyping in differential diagnosis of Alzheimer's disease
83. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
84. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
85. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
86. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease